The hemophilia treatment drugs market is experiencing entry of a large number of new drugs in the market. Few of them have already arrived and other long lasting clotting factors and more promising drugs are on their way to get launched in this market. For instance, follow up data from phase I/II study of hemophilia medicine ‘Emicizumab’ by Roche has demonstrated promising results regarding safety and prophylactic efficiency in people with severe hemophilia A. Another example is of ‘Eloctate’ for type A and ‘Aprolix’ for type B hemophilia, respectively. These two newly arrived biogen products are opposed to commonly prescribe course of three infusions per week as they are longer-acting than traditional treatments and require only one to two infusions per week, due to their new mechanism of action.
LPI (LP Information)' newest research report, the “Hemophilia Drugs Industry Forecast” looks at past sales and reviews total world Hemophilia Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Hemophilia Drugs sales for 2023 through 2029. With Hemophilia Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hemophilia Drugs industry.
This Insight Report provides a comprehensive analysis of the global Hemophilia Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hemophilia Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Hemophilia Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hemophilia Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hemophilia Drugs.
The global Hemophilia Drugs market size is projected to grow from US$ 12460 million in 2022 to US$ 16680 million in 2029; it is expected to grow at a CAGR of 16680 from 2023 to 2029.
With increasing attention on prophylactic treatment, the market for hemophilia drugs is estimated to have a positive outlook over the coming years. The prophylactic treatment approach prevents spontaneous bleeding episodes, significantly improves the quality of life in terms of physical activities, and maintains the level of clotting factors above a baseline. According to the studies conducted by the US National Library of Medicine determined that the savings on prophylactic treatment be approximately USD 8,312 to USD 17,675 per bleeding episode in a person. Moreover, this line of treatment reduces joint damage and suffering from pain. Several of such long-acting therapeutics are under development and expected to be launched over the next four years. The shift in preference for prophylactic treatment due to its advantages will drive this market’s growth over the forecast period.
This report presents a comprehensive overview, market shares, and growth opportunities of Hemophilia Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Hemophilia A
Inhibitors
Hemophilia B
Von Willebrand Disease
Segmentation by application
Recombinant Therapies
Plasma-Derived Therapies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Baxalta
Bayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hemophilia Drugs market?
What factors are driving Hemophilia Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hemophilia Drugs market opportunities vary by end market size?
How does Hemophilia Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Hemophilia Drugs Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for Hemophilia Drugs by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for Hemophilia Drugs by Country/Region, 2018, 2022 & 2029 2.2 Hemophilia Drugs Segment by Type 2.2.1 Hemophilia A 2.2.2 Inhibitors 2.2.3 Hemophilia B 2.2.4 Von Willebrand Disease 2.3 Hemophilia Drugs Sales by Type 2.3.1 Global Hemophilia Drugs Sales Market Share by Type (2018-2023) 2.3.2 Global Hemophilia Drugs Revenue and Market Share by Type (2018-2023) 2.3.3 Global Hemophilia Drugs Sale Price by Type (2018-2023) 2.4 Hemophilia Drugs Segment by Application 2.4.1 Recombinant Therapies 2.4.2 Plasma-Derived Therapies 2.5 Hemophilia Drugs Sales by Application 2.5.1 Global Hemophilia Drugs Sale Market Share by Application (2018-2023) 2.5.2 Global Hemophilia Drugs Revenue and Market Share by Application (2018-2023) 2.5.3 Global Hemophilia Drugs Sale Price by Application (2018-2023) 3 Global Hemophilia Drugs by Company 3.1 Global Hemophilia Drugs Breakdown Data by Company 3.1.1 Global Hemophilia Drugs Annual Sales by Company (2018-2023) 3.1.2 Global Hemophilia Drugs Sales Market Share by Company (2018-2023) 3.2 Global Hemophilia Drugs Annual Revenue by Company (2018-2023) 3.2.1 Global Hemophilia Drugs Revenue by Company (2018-2023) 3.2.2 Global Hemophilia Drugs Revenue Market Share by Company (2018-2023) 3.3 Global Hemophilia Drugs Sale Price by Company 3.4 Key Manufacturers Hemophilia Drugs Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Hemophilia Drugs Product Location Distribution 3.4.2 Players Hemophilia Drugs Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Hemophilia Drugs by Geographic Region 4.1 World Historic Hemophilia Drugs Market Size by Geographic Region (2018-2023) 4.1.1 Global Hemophilia Drugs Annual Sales by Geographic Region (2018-2023) 4.1.2 Global Hemophilia Drugs Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic Hemophilia Drugs Market Size by Country/Region (2018-2023) 4.2.1 Global Hemophilia Drugs Annual Sales by Country/Region (2018-2023) 4.2.2 Global Hemophilia Drugs Annual Revenue by Country/Region (2018-2023) 4.3 Americas Hemophilia Drugs Sales Growth 4.4 APAC Hemophilia Drugs Sales Growth 4.5 Europe Hemophilia Drugs Sales Growth 4.6 Middle East & Africa Hemophilia Drugs Sales Growth 5 Americas 5.1 Americas Hemophilia Drugs Sales by Country 5.1.1 Americas Hemophilia Drugs Sales by Country (2018-2023) 5.1.2 Americas Hemophilia Drugs Revenue by Country (2018-2023) 5.2 Americas Hemophilia Drugs Sales by Type 5.3 Americas Hemophilia Drugs Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Hemophilia Drugs Sales by Region 6.1.1 APAC Hemophilia Drugs Sales by Region (2018-2023) 6.1.2 APAC Hemophilia Drugs Revenue by Region (2018-2023) 6.2 APAC Hemophilia Drugs Sales by Type 6.3 APAC Hemophilia Drugs Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Hemophilia Drugs by Country 7.1.1 Europe Hemophilia Drugs Sales by Country (2018-2023) 7.1.2 Europe Hemophilia Drugs Revenue by Country (2018-2023) 7.2 Europe Hemophilia Drugs Sales by Type 7.3 Europe Hemophilia Drugs Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Hemophilia Drugs by Country 8.1.1 Middle East & Africa Hemophilia Drugs Sales by Country (2018-2023) 8.1.2 Middle East & Africa Hemophilia Drugs Revenue by Country (2018-2023) 8.2 Middle East & Africa Hemophilia Drugs Sales by Type 8.3 Middle East & Africa Hemophilia Drugs Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Hemophilia Drugs 10.3 Manufacturing Process Analysis of Hemophilia Drugs 10.4 Industry Chain Structure of Hemophilia Drugs 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Hemophilia Drugs Distributors 11.3 Hemophilia Drugs Customer 12 World Forecast Review for Hemophilia Drugs by Geographic Region 12.1 Global Hemophilia Drugs Market Size Forecast by Region 12.1.1 Global Hemophilia Drugs Forecast by Region (2024-2029) 12.1.2 Global Hemophilia Drugs Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Hemophilia Drugs Forecast by Type 12.7 Global Hemophilia Drugs Forecast by Application 13 Key Players Analysis 13.1 Baxalta 13.1.1 Baxalta Company Information 13.1.2 Baxalta Hemophilia Drugs Product Portfolios and Specifications 13.1.3 Baxalta Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 Baxalta Main Business Overview 13.1.5 Baxalta Latest Developments 13.2 Bayer 13.2.1 Bayer Company Information 13.2.2 Bayer Hemophilia Drugs Product Portfolios and Specifications 13.2.3 Bayer Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 Bayer Main Business Overview 13.2.5 Bayer Latest Developments 13.3 CSL Behring 13.3.1 CSL Behring Company Information 13.3.2 CSL Behring Hemophilia Drugs Product Portfolios and Specifications 13.3.3 CSL Behring Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 CSL Behring Main Business Overview 13.3.5 CSL Behring Latest Developments 13.4 Pfizer 13.4.1 Pfizer Company Information 13.4.2 Pfizer Hemophilia Drugs Product Portfolios and Specifications 13.4.3 Pfizer Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 Pfizer Main Business Overview 13.4.5 Pfizer Latest Developments 13.5 Alnylam Pharmaceuticals 13.5.1 Alnylam Pharmaceuticals Company Information 13.5.2 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolios and Specifications 13.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 Alnylam Pharmaceuticals Main Business Overview 13.5.5 Alnylam Pharmaceuticals Latest Developments 13.6 BioMarin 13.6.1 BioMarin Company Information 13.6.2 BioMarin Hemophilia Drugs Product Portfolios and Specifications 13.6.3 BioMarin Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 BioMarin Main Business Overview 13.6.5 BioMarin Latest Developments 13.7 Catalyst Biosciences 13.7.1 Catalyst Biosciences Company Information 13.7.2 Catalyst Biosciences Hemophilia Drugs Product Portfolios and Specifications 13.7.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 Catalyst Biosciences Main Business Overview 13.7.5 Catalyst Biosciences Latest Developments 13.8 Dimension Therapeutics 13.8.1 Dimension Therapeutics Company Information 13.8.2 Dimension Therapeutics Hemophilia Drugs Product Portfolios and Specifications 13.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 Dimension Therapeutics Main Business Overview 13.8.5 Dimension Therapeutics Latest Developments 13.9 F. Hoffmann-La Roche 13.9.1 F. Hoffmann-La Roche Company Information 13.9.2 F. Hoffmann-La Roche Hemophilia Drugs Product Portfolios and Specifications 13.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.9.4 F. Hoffmann-La Roche Main Business Overview 13.9.5 F. Hoffmann-La Roche Latest Developments 13.10 Grifols 13.10.1 Grifols Company Information 13.10.2 Grifols Hemophilia Drugs Product Portfolios and Specifications 13.10.3 Grifols Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.10.4 Grifols Main Business Overview 13.10.5 Grifols Latest Developments 13.11 Octapharma 13.11.1 Octapharma Company Information 13.11.2 Octapharma Hemophilia Drugs Product Portfolios and Specifications 13.11.3 Octapharma Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.11.4 Octapharma Main Business Overview 13.11.5 Octapharma Latest Developments 13.12 Sangamo Biosciences 13.12.1 Sangamo Biosciences Company Information 13.12.2 Sangamo Biosciences Hemophilia Drugs Product Portfolios and Specifications 13.12.3 Sangamo Biosciences Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.12.4 Sangamo Biosciences Main Business Overview 13.12.5 Sangamo Biosciences Latest Developments 13.13 Spark Therapeutics 13.13.1 Spark Therapeutics Company Information 13.13.2 Spark Therapeutics Hemophilia Drugs Product Portfolios and Specifications 13.13.3 Spark Therapeutics Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.13.4 Spark Therapeutics Main Business Overview 13.13.5 Spark Therapeutics Latest Developments 13.14 Swedish Orphan Biovitrum 13.14.1 Swedish Orphan Biovitrum Company Information 13.14.2 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolios and Specifications 13.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.14.4 Swedish Orphan Biovitrum Main Business Overview 13.14.5 Swedish Orphan Biovitrum Latest Developments 14 Research Findings and Conclusion